Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xyntha in Children < 6 Years with Hemophilia A
NCT00759655Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2009
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of moroctocog alfa in hemophilia A, sponsored by Pfizer. Primary endpoints: Percentage of Participants With Factor VIII (FVIII) Inhibitor Development at 24 months, Percentage of Participants With Less Than Expected Therapeutic Effects (LETE) in the On-Demand Setting at 24 months and 2 more. Started Jun 2009; status: terminated.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00759655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759655.